https://dmas.virginia.gov



600 East Broad Street Suite 1300 Richmond, VA 23219

## MEDICAID BULLETIN

Last Updated: 04/05/2022

# Coverage of additional COVID-19 antibody product and convalescent plasma for outpatient use

The purpose of this bulletin is to inform providers that DMAS fee-for-service (FFS) and all contracted managed care organizations (MCOs) will ensure coverage of the following for full benefit Medicaid and FAMIS members: 1) a COVID-19 antibody product (bebtelovimab), and 2) convalescent plasma for outpatient use in select patients. These are consistent with recent Federal Drug Administration's (FDA) Emergency Use Authorizations (EUAs) and associated amendments, in accordance with Section 6008(b)(4) of the Families First Coronavirus Response Act. For further information on COVID-19 monoclonal antibody product and vaccine administration coverage, please reference previous DMAS memos here: <a href="https://www.virginiamedicaid.dmas.virginia.gov/wps/portal/MedicaidMemostoProviders">https://www.virginiamedicaid.dmas.virginia.gov/wps/portal/MedicaidMemostoProviders</a>.

### **Coverage of COVID-19 Antibody Product (Bebtelovimab)**

In light of the FDA's amended EUA authorizing the COVID-19 antibody product listed below for treatment of individuals with COVID-19, the following antibody product and administration codes will be covered for FFS and MCO members with dates of service on and after the date of the FDA EUA (2/11/2022), and when *Requirements for Reimbursement of Antibody Products* are met (treatment has received FDA EUA or approval, AND patients meets the conditions of the FDA EUA or approval as of the date services are delivered), as outlined in the "<u>Updates to Coverage of COVID-19 Testing & Antibody Treatment</u>" memo dated 4/23/21. The most recent criteria for approved and authorized COVID-19 treatments can be found here:

https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs. FFS reimbursement rates are available for reference via the DMAS fee file. MCOs can be reached at the contacts listed at the end of this memo for MCO-specific reimbursement rates. Prior authorization is not required for either FFS or MCO members.

- Q0222\*: Injection, Bebtelovimab, 175mg
- **M0222**: Intravenous infusion, Bebtelovimab, includes infusion and post administration monitoring

\*The Centers for Medicare and Medicaid Services (CMS) anticipates that, at this time, providers will not incur a cost for COVID-19 monoclonal antibody products. Providers should not bill for a COVID-19 monoclonal antibody product if they received it for free.

#### **Coverage of Convalescent Plasma for Outpatient Use**

600 East Broad Street Suite 1300 Richmond, VA 23219 https://dmas.virginia.gov

## MEDICAID BULLETIN

In light of the FDA's amended EUA authorizing the outpatient use of the treatment listed below for certain individuals with COVID-19 infection, the following billing codes will be covered for FFS and MCO members with dates of service on and after the date of the FDA EUA amendment (12/28/2021), and when the *Requirements for Reimbursement of Convalescent Plasma* outlined below are met. FFS reimbursement rates are available for reference via the DMAS fee file. MCOs can be reached at the contacts listed at the end of this memo for MCO-specific reimbursement rates:

• **C9507**: Fresh frozen plasma, high titer COVID-19 convalescent, frozen within 8 hours of collection, each unit

Requirements for Reimbursement of Convalescent Plasma


Medical documentation for FFS and MCO members must demonstrate that the following requirements are met:

- treatment has an active <u>FDA</u> Emergency Use Authorization (EUA) or FDA approval as of the date the treatment is administered, AND
- patient meets the disease severity and risk of progression standards identified by the Infectious Diseases Society of America (IDSA) as appropriate for outpatient treatment with convalescent plasma for COVID-19, AND
- patient meets the immune status requirements outlined in the Limitations of Authorized Use or FDA approval, AND
- the patient is not eligible for, or does not have access to, other FDA authorized or approved treatment options for COVID-19, AND
- the collection, testing and administration of high-titer COVID-19 convalescent plasma is in compliance with <u>FDA guidance</u>

FFS claims submitted on or after the coverage dates listed above, which were initially denied on the grounds of non-coverage and which providers feel would now meet updated coverage criteria, may be resubmitted to DMAS FFS. Service authorization will not be required or enforced for FFS or MCO members.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

PROVIDER CONTACT INFORMATION & RESOURCES	
Virginia Medicaid Web Portal Automated Response System (ARS) Member eligibility, claims status, payment status, service limits, service authorization status, and remittance advice.	Through March 29: <a href="https://login.vamedicaid.dmas.virginia.gov/">www.virginiamedicaid.dmas.virginia.gov/</a> As of April 4, 2022: <a href="https://login.vamedicaid.dmas.virginia.gov/">https://login.vamedicaid.dmas.virginia.gov/</a>
Medicall (Audio Response System) Member eligibility, claims status, payment status, service limits, service authorization status, and remittance advice.	1-800-884-9730 or 1-800-772-9996
<b>KEPRO</b> Service authorization information for feefor-service members.	https://dmas.kepro.com/



https://dmas.virginia.gov

# **MEDICAID BULLETIN**

**Provider Appeals** 

DMAS launched an appeals portal in 2021. You can use this portal to file appeals and track the status of your appeals. Visit the website listed for appeal resources and to register for the portal.

https://www.dmas.virginia.gov/appeals/

#### Provider Audits

Please continue to adhere to all instructions provided via DMAS or its contractors as it relates to complying with audit processes and procedures. Conversion to MES will not affect audit protocol.

#### **Managed Care Programs**

Medallion 4.0, Commonwealth Coordinated Care Plus (CCC Plus), and Program of All-Inclusive Care for the Elderly (PACE). In order to be reimbursed for services provided to a managed care enrolled individual, providers must follow their respective contract with the managed care plan/PACE provider. The managed care plan may utilize different quidelines than those described for Medicaid fee-for-service individuals.

	managed care plan may utilize different guidelines than those described for Medicaid fee-for-service individuals.	
Medallion 4.0	https://www.dmas.virginia.gov/for-providers/managed-care/medallion-40/	
CCC Plus	https://www.dmas.virginia.gov/for-providers/managed-care/ccc-plus/	
PACE	https://www.dmas.virginia.gov/for-providers/long-term-care/programs-and-initiatives/program-of-all-inclusive-care/	
Magellan Behavioral Health Behavioral Health Services Administrator, check eligibility, claim status, service limits, and service authorizations for fee- for-service members.	www.MagellanHealth.com/Provider For credentialing and behavioral health service information, visit: www.magellanofvirginia.com, email: VAProviderQuestions@MagellanHealth.com,or Call: 1-800-424-4046	
Provider HELPLINE for claims assistance only as of March 26, 2022 Monday-Friday 8:00 a.m5:00 p.m. For provider use only, have Medicaid Provider ID Number available.	1-804-786-6273 1-800-552-8627	
Provider Enrollment and Management Help Desk Monday-Friday 8:00 a.m5:00 p.m. For provider use only, have Medicaid Provider ID Number available.	1-804-270-5105 1-888-829-5373	
Aetna Better Health of Virginia	www.aetnabetterhealth.com/Virginia 1-800-279-1878	
Anthem HealthKeepers Plus	www.anthem.com/vamedicaid 1-800-901-0020	
Molina Complete Care	1-800-424-4524 (CCC+) 1-800-424-4518 (M4)	
Optima Family Care	1-800-881-2166 www.optimahealth.com/medicaid	
United Healthcare	www.Uhccommunityplan.com/VA and www.myuhc.com/communityplan 1-844-752-9434, TTY 711	
Virginia Premier	1-800-727-7536 (TTY: 711), <u>www.virginiapremier.com</u>	